Parkinson's Disease Therapeutics Market Size in the US was ~USD 1,883 Million in 2023, is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Parkinson's Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Parkinson's disease, historical and forecasted epidemiology as well as the Parkinson's disease market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Parkinson's Disease Market Share @ Parkinson's Disease Market Outlook- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Parkinson's Disease Market Report
• In March 2025:- UCB Biopharma SRL conducted a study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
• In March 2025, MedRhythms announced that MR-005, its neurorehabilitation system designed to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), has been classified as a Class II, Rx-only medical device by the U.S. Food and Drug Administration (FDA). The system will be marketed under the brand name Movive.
• In March 2025, Medtronic plc, a global leader in healthcare technology, announced the FDA approval of BrainSenseTM Adaptive deep brain stimulation (aDBS) and BrainSenseTM Electrode Identifier (EI). While there is no cure for debilitating neurological conditions like Parkinson's, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson's and other neurological disorders for over 30 years.
• In Feb 2025, Medtronic received FDA approval for its BrainSenseTM Adaptive deep brain stimulation (aDBS) for Parkinson's disease, marking a significant advancement in neuromodulation therapy.
• In February 2025, AB-1005, AskBio's investigational gene therapy for Parkinson's disease, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA to accelerate its development and review for treating serious or life-threatening conditions.
• In February 2025, the U.S. FDA approved Ctexli (chenodiol) for treating cerebrotendinous xanthomatosis (CTX) in adults, making it the first FDA-approved drug for this rare lipid storage disease.
• In February 2025, Newronika received FDA Investigational Device Exemption (IDE) clearance to begin a pivotal U.S. clinical trial. The trial will assess the safety and efficacy of its adaptive deep brain stimulation system for patients with movement disorders, including Parkinson's disease.
• In February 2025, Supernus Pharmaceuticals, Inc. announced that the U.S. FDA approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease.
• According to DelveInsight's epidemiology model, the total diagnosed prevalent cases of Parkinson's disease were approximately 1,210 thousand in the US in 2023 which is expected to increase during the forecast period (2024-2034) due to increasing awareness, aging population, and advancement of diagnostic procedures.
• In the 7MM, Japan accounted for approximately 258 thousand cases diagnosed prevalent cases of Parkinson's disease in 2023.
• Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Parkinson's disease with nearly 495 thousand cases in 2023 followed by France accounting for approximately 277 thousand cases. On the other hand, Spain accounted for the least with nearly 149 thousand cases.
• In 2023, Japan accounted for approximately 135 thousand cases in males and 123 thousand cases in females, based on gender-specific diagnosed prevalent cases of Parkinson's disease. These cases are expected to increase during the forecast period.
• In the US, nearly 19 thousand cases were diagnosed with Parkinson's disease in the age group =49 years, 215 thousand cases in 50-64 years, 449 thousand cases in 65-74 years, and 527 thousand cases in =75 years in 2023.
• Among the stage-specific diagnosed prevalent cases of Parkinson's disease in Japan, there were approximately 9 thousand cases for Stage I, 40 thousand cases for Stage II, 107 thousand cases for Stage III, 70 thousand cases for Stage IV, and 31 thousand cases for Stage V in 2023.
• In Japan, there were approximately 73 thousand cases of psychosis associated with Parkinson's disease in 2023.
• In the assessment done by DelveInsight, the estimated Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the US were nearly 508 thousand in 2023.
• The leading Parkinson's Disease Companies such as Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd., and others.
• Promising Parkinson's Disease Pipeline Therapies such as VTX3232, Rasagiline, Safinamide Methanesulfonate, Kinesia-ONETM, Levetiracetam, CVXL-0107, and others.

Stay ahead in the Parkinson's Disease Therapeutics Market with DelveInsight's Strategic Report @ Parkinson's Disease Market Outlook- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Epidemiology Segmentation in the 7MM
• Total Parkinson's Disease Diagnosed Prevalent Cases
• Total Parkinson's Disease Diagnosed Prevalent Cases
• Total Parkinson's Disease Treated Cases

Download the report to understand which factors are driving Parkinson's Disease Epidemiology trends @ Parkinson's Disease Prevalence- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Marketed Drugs
• CREXONT (carbidopa and levodopa) ER capsules: Amneal Pharmaceuticals
CREXONT is a novel oral formulation of carbidopa/levodopa (CD/LD) that combines immediate-release (IR) granules and extended-release (ER) pellets. This prescription medication is used to treat Parkinson's disease, Parkinson's disease caused by brain infection or inflammation, and Parkinson's disease-like symptoms resulting from carbon monoxide or manganese poisoning in adults. The ER beads in CREXONT consist of levodopa (LD), coated with a sustained-release polymer for slow drug release, a mucoadhesive polymer to ensure the granules remain at the absorption site longer, and an enteric coating to prevent premature disintegration in the stomach. This formulation is distinct from RYTARY (carbidopa/levodopa) extended-release capsules, Amneal's extended-release CD/LD treatment for Parkinson's disease approved by the US FDA in 2015.

• PRODUODOPA (foslevodopa/foscarbidopa): AbbVie
PRODUODOPA is the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating severe motor fluctuations in advanced Parkinson's disease patients whose symptoms are inadequately controlled by other therapies. The continuous delivery of PRODUODOPA provides levodopa 24 hours a day, potentially extending the period of well-controlled symptoms, often referred to as "On" time. AbbVie received marketing authorization for PRODUODOPA through the decentralized procedure in the third quarter of 2022.

• XADAGO/EQUFINA (safinamide): Newron Pharmaceuticals/ Zambon/ Supernus Pharmaceuticals/ Eisai
XADAGO is an inhibitor of monoamine oxidase B (MAO-B) indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. The precise mechanism by which XADAGO exerts its effect on Parkinson's disease is unknown. However, it is believed that by inhibiting MAO-B activity and blocking the catabolism of dopamine, there is an increase in dopamine levels and subsequent dopaminergic activity in the brain. XADAGO tablets contain safinamide as the mesylate salt and are available as 50 mg and 100 mg film-coated tablets for oral administration. Each tablet contains 65.88 mg or 131.76 mg of safinamide mesylate, equivalent to 50 mg or 100 mg of the safinamide-free base, respectively.

Parkinson's Disease Emerging Drugs
• SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals
SPN-830 (apomorphine infusion device) is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease patients that are not adequately controlled with oral levodopa and one or more adjunct Parkinson's disease medications. SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion pump under the skin for 14-18 h. The target infusion rate ranged between 3 mg and 8 mg per h. The thin, small needle applied underneath the skin is usually placed on the abdomen or upper thigh. Such administration has the potential to be less invasive, with fewer injection sites, and is more convenient than Supernus Pharmaceutical's already approved product APOKYN, which mimics the action of dopamine in the brain, is intended to reduce off periods on demand, and is administered under the skin.
• Tavapadon: AbbVie (Cerevel Therapeutics)
Cerevel Therapeutics is developing tavapadon FDA approval to treat both early and late-stage Parkinson's disease. Tavapadon FDA approval was rationally designed as an orally bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes to balance meaningful motor activity with a favourable safety profile.

• P2B001 (extended-release pramipexole and rasagiline): Pharma Two B
P2B001, being developed by Pharma Two B, is a novel, once-daily combination of extended-release pramipexole, a low-dose dopamine agonist, and rasagiline, a low-dose MAO-B inhibitor for the treatment of Parkinson's disease. Pramipexole mimics the effects of dopamine while minimizing the breakdown of dopamine.

To learn more about Parkinson's Disease treatment guidelines, visit @ Parkinson's Disease Treatment Market Landscape- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Market Outlook
Parkinson's disease is a progressively worsening neurodegenerative disorder with an unclear cause and pathogenesis. Its global burden is increasing, driven by aging populations and environmental factors. Classic symptoms include motor issues like bradykinesia, rigidity, tremors, and postural instability, along with non-motor symptoms such as depression, cognitive impairment, and autonomic disturbances, which significantly affect quality of life. Diagnosing Parkinson's is challenging due to symptom overlap with other movement disorders, with imaging like PET scans aiding in diagnosis.

Parkinson's Disease Psychosis Therapies and Companies
• Crenolanib: Arog Pharmaceuticals
• TAS-116: Taiho Pharmaceutical
• Bezuclastinib (CGT9486/PLX9486): Cogent Biosciences, Inc. / Plexxikon Inc.

Learn more about the FDA-approved drugs for Parkinson's Disease @ Drugs for Parkinson's Disease Treatment- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Parkinson's Disease Psychosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Parkinson's Disease Psychosis Companies: Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd., and others.
• Key Parkinson's Disease Psychosis Therapies: ENT-012 and others.
• Parkinson's Disease Psychosis Therapeutic Assessment: Parkinson's Disease Psychosis current marketed and Parkinson's Disease Psychosis emerging therapies
• Parkinson's Disease Psychosis Market Dynamics: Parkinson's Disease Psychosis market drivers and Parkinson's Disease Psychosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Parkinson's Disease Psychosis Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Psychosis Market Access and Reimbursement

Discover more about Parkinson's Disease Drugs in development @ Parkinson's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Parkinson's Disease Psychosis Market Report Introduction
2. Executive Summary for Parkinson's Disease Psychosis
3. SWOT analysis of Parkinson's Disease Psychosis
4. Parkinson's Disease Psychosis Patient Share (%) Overview at a Glance
5. Parkinson's Disease Psychosis Market Overview at a Glance
6. Parkinson's Disease Psychosis Disease Background and Overview
7. Parkinson's Disease Psychosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Parkinson's Disease Psychosis
9. Parkinson's Disease Psychosis Current Treatment and Medical Practices
10. Parkinson's Disease Psychosis Unmet Needs
11. Parkinson's Disease Psychosis Emerging Therapies
12. Parkinson's Disease Psychosis Market Outlook
13. Country-Wise Parkinson's Disease Psychosis Market Analysis (2020-2034)
14. Parkinson's Disease Psychosis Market Access and Reimbursement of Therapies
15. Parkinson's Disease Psychosis Market Drivers
16. Parkinson's Disease Psychosis Market Barriers
17. Parkinson's Disease Psychosis Appendix
18. Parkinson's Disease Psychosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.